Physician profile
Vanessa Workinger
NPI 1194427344
$688.04
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.26 · 2023: $114 · 2024: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $71.53 | 2024 | Repatha, Otezla |
| Novo Nordisk INC | $70.97 | 2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $66.44 | 2024 | Spravato |
| Pfizer INC. | $62.83 | 2024 | |
| Dexcom, INC. | $57.01 | 2024 | Dexcom G6 Transmitter |
| Indivior INC. | $55.75 | 2024 | Sublocade |
| Lilly USA, LLC | $42.69 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $42.52 | 2023-2024 | |
| Inspire Medical Systems, INC. | $34.72 | 2023 | Inspire |
| Boston Scientific Corporation | $33.78 | 2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.67 | 2024 | Xifaxan, Trulance |
| Mannkind Corporation | $25.35 | 2023 | Afrezza |
| Glaxosmithkline, LLC. | $22.26 | 2022 | |
| Axsome Therapeutics, INC. | $20.86 | 2024 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $19.90 | 2024 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.55 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $13.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Workinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.